We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Details Reasons for Breakthrough Therapy Designation Denials
FDA Details Reasons for Breakthrough Therapy Designation Denials
June 28, 2013
The FDA offered some hints last week about why it has denied a third of drugmakers’ breakthrough therapy designation requests, with premature clinical data being the primary culprit.